Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $10.80.

A number of equities research analysts have issued reports on the company. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Tuesday. Jefferies Financial Group started coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Sana Biotechnology in a report on Tuesday.

Sana Biotechnology Stock Down 17.7 %

Sana Biotechnology stock opened at $2.28 on Friday. Sana Biotechnology has a 52-week low of $1.52 and a 52-week high of $10.50. The firm has a market cap of $509.05 million, a PE ratio of -1.63 and a beta of 1.63. The company’s 50 day moving average is $3.06 and its two-hundred day moving average is $3.20.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.02. On average, equities research analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insider Buying and Selling at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 31.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sana Biotechnology

Several large investors have recently modified their holdings of SANA. Cerity Partners LLC purchased a new stake in Sana Biotechnology in the 4th quarter valued at $25,000. Tower Research Capital LLC TRC increased its stake in Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after purchasing an additional 10,548 shares during the period. Syon Capital LLC acquired a new stake in shares of Sana Biotechnology during the fourth quarter worth about $27,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the third quarter worth about $29,000. Finally, Ameriprise Financial Inc. acquired a new position in Sana Biotechnology in the 4th quarter valued at about $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.